Advance care planning – a multi-centre cluster randomised clinical trial: the research protocol of the ACTION study by Rietjens, Judith A. C. et al.
STUDY PROTOCOL Open Access
Advance care planning – a multi-centre
cluster randomised clinical trial: the
research protocol of the ACTION study
Judith A. C. Rietjens1*†, Ida J. Korfage1†, Lesley Dunleavy2, Nancy J. Preston2, Lea J. Jabbarian1,
Caroline Arnfeldt Christensen3, Maja de Brito8, Francesco Bulli6, Glenys Caswell7, Branka Červ8,
Johannes van Delden9, Luc Deliens10,12, Giuseppe Gorini6, Mogens Groenvold3,4, Dirk Houttekier10,
Francesca Ingravallo11, Marijke C. Kars9, Urška Lunder8, Guido Miccinesi6, Alenka Mimić8, Eugenio Paci6,
Sheila Payne2, Suzanne Polinder1, Kristian Pollock7, Jane Seymour7, Anja Simonič8, Anna Thit Johnsen4,5,
Mariëtte N. Verkissen10, Esther de Vries1, Andrew Wilcock13, Marieke Zwakman9 and Agnes van der Heide (Pl)1
Abstract
Background: Awareness of preferences regarding medical care should be a central component of the care of
patients with advanced cancer. Open communication can facilitate this but can occur in an ad hoc or variable
manner. Advance care planning (ACP) is a formalized process of communication between patients, relatives and
professional caregivers about patients’ values and care preferences. It raises awareness of the need to anticipate
possible future deterioration of health. ACP has the potential to improve current and future healthcare decision-
making, provide patients with a sense of control, and improve their quality of life.
Methods/Design: We will study the effects of the ACP program Respecting Choices on the quality of life of
patients with advanced lung or colorectal cancer. In a phase III multicenter cluster randomised controlled trial, 22
hospitals in 6 countries will be randomised. In the intervention sites, patients will be offered interviews with a
trained facilitator. In the control sites, patients will receive care as usual. In total, 1360 patients will be included. All
participating patients will be asked to complete questionnaires at inclusion, and again after 2.5 and 4.5 months. If a
patient dies within a year after inclusion, a relative will be asked to complete a questionnaire on end-of-life care.
Use of medical care will be assessed by checking medical files. The primary endpoint is patients’ quality of life at
2.5 months post-inclusion. Secondary endpoints are the extent to which care as received is aligned with patients’
preferences, patients’ evaluation of decision-making processes, quality of end-of-life care and cost-effectiveness of
the intervention. A complementary qualitative study will be carried out to explore the lived experience of
engagement with the Respecting Choices program from the perspectives of patients, their Personal
Representatives, healthcare providers and facilitators.
Discussion: Transferring the concept of ACP from care of the elderly to patients with advanced cancer, who on
average are younger and retain their mental capacity for a larger part of their disease trajectory, is an important
next step in an era of increased focus on patient centered healthcare and shared decision-making.
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Background
Despite progress in diagnosis and treatment, cancer re-
mains a major life limiting disease, with 14.1 million
new cases and 8.2 million deaths worldwide in 2012 [1].
Patients with advanced cancer typically suffer from a re-
duced quality of life and multiple symptoms, such as
pain, fatigue, and dyspnoea, due to their illness and/or
its treatment [2]. A diagnosis of advanced cancer often
has a tremendous impact on patients’ emotional well-
being and may result in depression, anxiety and a feeling
of loss of control [3, 4]. Ideally, these patients receive
patient-centered care, addressing their needs concerning
symptom control, psychosocial support, spiritual sup-
port, and practical issues. Patients’ preferences regarding
care and their wishes concerning their place of residence
at the end of life should be central in the decision-
making. Currently, treatment aimed at prolonging life
has been found to often prevail over care aimed at re-
lieving patients’ suffering and enhancing their quality of
life, which may not always be in accordance with pa-
tients’ needs and preferences [5].
Timely and efficient communication is an important
prerequisite for care that adequately addresses patients’
needs and preferences [6]. However, research findings
consistently demonstrate that communication between
physicians, patients with advanced cancer and their rela-
tives is complex. Physicians tend to focus on treatment
[7], patients may be overwhelmed and unaware of the
possibility to opt for treatment aimed at relieving suffer-
ing, and relatives may feel stressed and uncertain to be
involved in medical decisions without being aware of
their beloved one’s preferences [8].
Advance care planning has moved from being a
process which aims to elicit specific instructions about
medical treatment at the end of life, to being recognized
as an opportunity to help patients and their families to
prepare, in their own terms, for the changes wrought by
serious progressive illness and work with them to plan
nursing, social and medical care so that it better fits
their needs, hopes and aspirations [9]. ACP is a formal-
ized process of communication between patients, rela-
tives and professional caregivers. It has been defined as
“a voluntary process of discussion about future care
between an individual and their care providers, irre-
spective of discipline. […] It is recommended that with
the individual’s agreement this discussion is docu-
mented, regularly reviewed, and communicated to key
persons involved in their care” [10]. ACP promotes dis-
cussion of preferences and communication of these pref-
erences to family, friends and healthcare professionals.
Patients are encouraged to document their preferences
in an advance directive and to review these preferences
as circumstances change. Patients are also encouraged to
appoint a personal representative, who can express their
preferences if they are unable to do so themselves. How-
ever, the legal status of advance directives and personal
representatives differs across countries. A review of the
literature [11] shows that ACP programs have the poten-
tial to improve communication between patients and
healthcare professionals, increase the quality of life and
well-being of patients and their relatives, reduce the use
of futile treatments and unnecessary hospitalisations, en-
hance provision of care that is consistent with patient
goals, and increase patients’ satisfaction with care. Other
studies have shown that ACP can reduce healthcare
costs [12–14]. The Respecting Choices program is one
of the most promising ACP program. This program was
developed in the US and successfully trialed in a geriat-
ric setting in Australia, showing that patients’ end of life
care wishes were much more likely to be known and
followed in the intervention group (86 %) compared to
the control group (30 %).
Most ACP studies have been performed in the US,
amongst nursing home patients with the main aim of es-
tablishing patients’ preferences before they lose their
competence. We will conduct our study in a European
context and hypothesize that ACP can also be effective
in improving the quality of life of patients with cancer
who often remain competent until death or very close to
death. ACP may support them in timely recognizing and
continuously expressing their core values and prefer-
ences, and to communicate these with their loved ones
and professional care givers, which will enable strategic
and effective planning of care and decision-making. As a
result, care may more adequately address patients’ values
and preferences, which may result in improved quality
of life and more adequate symptom control, while pa-
tients feel more in control and receive less unwanted or
futile interventions.
The overall hypothesis that will be studied in the
ACTION project is that a formalized ACP program
such as Respecting Choices significantly improves
the quality of life and reduces the symptom burden
of patients with advanced lung or colorectal cancer.
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The primary objective is to assess the effect of the
Respecting Choices ACP program on the quality of life
and symptoms of patients with advanced lung or colo-
rectal cancer.
The secondary objectives are:
1. To assess the effect of the Respecting Choices ACP
program on the quality of life and symptoms of
patients with advanced cancer in different subgroups
(gender, age, education, ethnicity, country and type
of cancer).
2. To assess the effect of the Respecting Choices ACP
program on the extent to which care as received is
in line with patients’ documented preferences, on
patients’ evaluation of the quality of the decision-
making process, and on how they cope with their
illness.
3. To assess patient satisfaction with the Respecting
Choices ACP program.
4. To assess the effect of the Respecting Choices ACP
program on the quality of end of life care of patients
with advanced cancer from the bereaved carers’
perspective, and on the wellbeing of these carers.
5. To assess the cost effectiveness of the Respecting
Choices ACP program.
6. To gain insight into how patients, patients’ relatives
and professional caregivers experience and respond
to facilitated ACP.
Methods/design
Study design and setting
We will perform a multicenter cluster-randomised clin-
ical trial in 22 hospitals in six European countries
(Belgium, Denmark, Italy, the Netherlands, Slovenia and
the United Kingdom). Per country pairs of comparable
hospitals (academic/non-academic) will be randomised
to provide either ‘care as usual’ supplemented with ACP
or ‘care as usual’. Cluster-randomisation prevents health-
care providers from giving patients in the control group
(‘care as usual’) more opportunity to discuss their prefer-
ences than usual due to their experience with providing
the intervention in the intervention group (‘care as usual’
supplemented with ACP). The nature of the intervention
makes blinding, for both healthcare professionals and
patients and their relatives, impossible.
Study population
In total, 1,360 patients with advanced lung (N = 680) or
colorectal cancer (N = 680) will be included. Lung and
colorectal cancer patients are selected for this study be-
cause both types of cancer have high incidence and mor-
tality rates in Europe and affect both sexes; see Table 1
for in- and exclusion criteria. At inclusion, the average
life expectancy of these patients is about one year; their
minimum estimated life expectancy to be eligible for the
study is three months.
Intervention
In this study, we will evaluate the ACP Respecting Choices
program. It involves trained healthcare professionals (“facil-
itators”, mostly nurses) who assist patients and their rela-
tives in reflecting on the patient’s goals, values and beliefs
and in discussing their healthcare wishes [12, 15]. The pro-
gram also supports people to identify specific activities
and experiences that may contribute to, or detract from,
their quality of life. Patients are encouraged to appoint a
patient representative who preferably also attends the Re-
specting Choices sessions, and to document their prefer-
ences for (future) medical treatment and care in an
advance directive; the so-called My Preferences form.
These wishes can e.g. concern the (non-)use of potentially
burdensome life-prolonging interventions such as hospita-
lisations or cardio-pulmonary resuscitation. Patients are
encouraged to discuss their preferences and questions
they may encounter with their physician. The content of
the communication during these meetings will be struc-
tured by the use of interview guides.
Study procedures
For each participating hospital, baseline background data
will be collected, such as number of cancer patients at-
tending annually, academic/nonacademic setting, num-
ber of beds and palliative care services, and a description
of common practices regarding ACP and decision-
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Histologically confirmed diagnosis of:
• Lung cancer:
Age < 18 years
- small cell - extensive disease/Stage III or IV*
- non-small cell - stage III or IV*
Unable to provide consent
• Colorectal cancer: Stage IV or metachronous metastases* Unable to complete questionnaire in country’s language
*according to 7th edition of TNM classification and staging system Less than 3 months anticipated life expectancy
Written informed consent to participate Taking part in a research study that is evaluating palliative
care services or communication strategies.
WHO performance status of 0–3.
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making at the end-of-life. In addition, background re-
ports for each of the six participating countries will be
created summarizing baseline national and local policies
related to the provision of palliative care and ACP.
We will carefully translate the Respecting Choices pro-
gram into the required European languages and adapt its
content, in close collaboration with the US developers, to
the specific legal, clinical, ethical, and cultural contexts of
the participating European countries. To test the interven-
tion and the process for acceptability and efficiency, a feasi-
bility study will be conducted with five patients and
potentially their family caregiver in each country. The pa-
tients will be offered the ACP program and will subse-
quently be interviewed. We will also test the questionnaires
and have conversations with their healthcare providers.
Extensive training of the ACP facilitators is essential in
this project. We will use the well-established structure of
the training and implementation of the Respecting
Choices program and will adopt a two-step education
process. First, one representative per country will be
trained in La Crosse, Wisconsin (USA) by the instruc-
tors of the Respecting Choices program. Subsequently,
the country representative will train the local facilitators,
who will be –where possible- selected among the health-
care workers of the hospitals, e.g. nurses. All together
about 40 facilitators will be trained in the project.
Patients will be followed until one year after inclusion.
During the inclusion period eligible patients in both
intervention and control hospitals, will be approached
for written informed consent. The information provided
in the consent form for the intervention group and the
control group will be as similar as possible to avoid se-
lection bias with respect to interest in ACP. However, to
minimize contamination, patients will be informed that
the project aims at investigating the experiences of pa-
tients with different approaches towards medical
decision-making in advanced stages of cancer, but no or
limited details of the Respecting Choices program will
be revealed in the control group. Patients will be given
ample time to consider participation and they are free
to withdraw from participating in the study without any
effect on their care.
Patients in the intervention group will be offered the
Respecting Choices program in addition to their usual
care. Depending on the health status of the patient and
the content of the conversations, a facilitated interview
will last 45–60 min on average. We plan to have one or
two sessions per patient. The facilitator will assist the
patient in documenting preferences, including the as-
signment of a personal representative. For quality assur-
ance, the interviews will be audio recorded by the
facilitator.
By a standardized checklist a proportion of the inter-
views will be rated for intervention fidelity [16].
Ethical committee procedures have been followed in
all countries and institutions involved, and approval has
been provided. The names of the main IRB’s are:
The Netherlands: Medische Ethische Toetsings
Commissie (METC) ErasmusMC;
Belgium: Universitair Ziekenhuis Brussel Commissie
Medische Ethiek;
United Kingdom: NRES Committee North
West - Liverpool East;
Italy: Comitato Etico Area Vasta Centro, Regione
Toscana;
Denmark: De Videnskabsetiske Komiteer for Region
Hovedstaden;
Slovenia: Komisija Republike Slovenije za medicinsko
etiko (KME).
Approval was also obtained from the IRB’s of all the
remaining institutions.
The trial is registered in the International Standard Ran-
domised Controlled Trial Number (ISRCTN63110516). A
Data Steering Monitoring Board (DSMB) will be
established.
Measurements
In ACTION, the following measurements will be per-
formed (see Table 2):
a) Questionnaire study. Patients will be asked to
complete a written questionnaire about quality of
life, symptoms, the decision-making process,
patient activation, coping, and satisfaction with
care (and the intervention) at baseline (i.e., the
moment of inclusion, before the ACP program is
delivered in the intervention group), and at 2.5 and
4.5 months after inclusion. If a patient dies during
follow up (i.e., within one year after inclusion), a
relative identified by the patient as next of kin will
receive a questionnaire to assess the patient’s
quality of end-of-life care and the relative’s own
wellbeing.
b) Medical file study. Data on patients’ survival will
be collected, as well as preferences as
documented and care as received to assess
whether patients’ preferred care was congruent
with received care. Data on care as received will
also be used in the cost-effectiveness analysis.
These medical files will be studied one year
post-inclusion with a checklist.
c) Study of recorded ACP sessions. Data will be
obtained from audio recorded facilitated interview
sessions. Compliance with the intervention will be
systematically evaluated with a predefined
checklist.
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Data management
Our data collection tool GemsTracker will be used to
safely store data of all participating patients across hospi-
tals and countries. GemsTracker enables restricted access
to selected parts of its content. Legislation in the partici-
pating countries for research on humans, not involving
medical products, will be taken into account [17–22].
Power calculation, sample size and feasibility of
recruitment
With at least 11 intervention and 11 control hospitals
each recruiting 34 lung cancer patients and 34 colorectal
cancer patients (of which 25 in each tumour type group
are expected to remain in the study until at least month
2.5), this multicentre cluster-randomised clinical trial
has an overall power of 90 % to identify a minimum dif-
ference between intervention and control groups of half
a standard deviation on the emotional functioning scale
of the QLQ-C30 scale, assuming an intra-class correl-
ation (ICC) of 0.1. On country level, these numbers give
a power of 50 % to show such a difference (assuming an
ICC of 0.05).
The main outcomes are measured at 2.5 months post-
inclusion. Although included patients have an average
life expectancy of at least 3 months, we expect that a
number of them will die within 2.5 months after inclu-
sion. Based on Dutch colorectal and lung cancer survival
statistics [23], we conservatively assume that this will be
the case for 15 % of included patients. Furthermore, we
anticipate that around 10 % of included patients may
drop out of the study for other reasons, resulting in a
total attrition rate of 25 %. Based on this attrition rate
and an estimated willingness of patients to participate of
33 %, the total number of eligible patients per hospital
per cancer type needs to be 101 in a 2-year period,
which is feasible in the participating hospitals.
Analyses
Analyses of the primary and secondary endpoints will be
performed following the intention-to-treat principle. De-
scriptive statistics will be used to summarize characteristics
of countries, hospitals and patients. Patient characteristics
(age, gender, socio-economic class, educational level) will
be compared at baseline between the intervention and con-
trol group. A multilevel modelling approach will be used to
examine differences in the endpoints between the interven-
tion and control groups, taking account of clustering effects
at both hospital and country-level. All statistical tests will
be two-sided and considered significant if p < 0.05.
Repeated-measures analyses of variance will be conducted
to assess the development of endpoints over time.
Subgroup analysis will be conducted by means of for-
mal interaction tests for intervention and those variables
which are more likely to influence the effect of the inter-
vention itself: gender, age class (<65, 65–74, 75+), educa-
tional status, and country.
Those conducting the data analysis will be blinded as
to whether the patient was included in the intervention
group or in the control group.
Qualitative study
A complementary qualitative study will be carried out in
at least 3 of the 6 countries, to qualitatively explore the
lived experience of engagement with the Respecting
Choices intervention from the perspectives of patients,
their Personal Representatives, healthcare providers and
Respecting Choices facilitators. The patient and Personal
Representative will undertake a facilitated advance care
planning (ACP) conversation following the Respecting
Choices program. Within two weeks of completing the
ACP program they will be invited to take part in a base-
line qualitative interview about their experiences. A fol-
low up interview will occur 10–14 weeks after the initial
intervention. At this second interview the patient will be
asked whether he or she has discussed the Respecting
Choices intervention with anyone from the healthcare
Table 2 Patient and bereaved carer endpoints of the project
I. Measured by questionnaire Measure
Primary endpoints:
- Quality of life EORTC QLQ-C30 4-item emotional
functioning scale [24]
EORTC emotional functioning short-
form based on CAT item bank
- Symptoms EORTC QLQ-C15-PAL [25]
Secondary endpoints:
- Shared decision-making APECC [26]
- Patient involvement Self-constructed questions
- Satisfaction with care EORTC IN–PATSAT32 [27]
- Coping with illness COPE [28–30]
- Satisfaction with the
intervention
Self-constructed questions
- Socio demographic measures Self-constructed questions
- Quality of end-of-life care VOICES-SF [31]a
- Bereaved carer wellbeing HADS [32]; IES [33]a
II. Obtained from medical files
- Survival; date and place of death (if applicable)
- Completion and content of advance directives; preferences
for care; assignment of proxy decision-maker; physician orders
- Diagnostic procedures and treatments received by the patient,
hospitalisations and specialist palliative care input.
III. Obtained from intervention sessions and qualitative interviews
Systematic cross-cultural comparison of patient experiences,
responses and concerns.
aThese endpoints are measured by the bereaved carer questionnaire and not
by the patient questionnaire
Rietjens et al. BMC Cancer  (2016) 16:264 Page 5 of 8
team and for consent to contact this person. If the pa-
tient dies before the second interview, the Personal
Representative will be contacted and invited for a quali-
tative interview. This will not be arranged until a mini-
mum of six weeks after the patient’s death. Healthcare
professionals identified by the patient as being closely in-
volved in the care will be invited to participate in a single
face to face, Skype or telephone interview. Respecting
Choices facilitators will be invited to participate in a single
focus group discussion. In each of the participating coun-
tries, the qualitative study will involve between 6–10 cases
including a patient and where appropriate a Personal
Representative and healthcare professionals. All interviews
and focus groups will be recorded and transcribed verba-
tim. Data will be thematically analysed using a pre-defined
coding framework which will be developed through an it-
erative process of discussion and consensus among the re-
search team.
Cost-effectiveness study
The economic evaluation will be performed from a
healthcare perspective, for a period of one year post-
inclusion per patient. Data on total in-hospital medical
care will be obtained from medical files, using a stan-
dardized and piloted data extraction form. Medical costs
will be calculated by multiplying the volumes of health-
care use with the corresponding unit prices. Unit prices
will be calculated for all six countries separately. Costs
for inpatient days in hospital will be estimated as real,
basic costs per day using detailed administrative infor-
mation. For other cost prices we will use charges. The
unit price of the ACP intervention will be determined
with the micro-costing method, which is based on a de-
tailed assessment of all resources used. To compare the
relative costs and outcomes of ACP versus ‘care as usual’
we will calculate the Incremental Cost Effectiveness Ra-
tio (ICER); the average additional costs of ACP divided
by the average change in emotional functioning mea-
sured with the EORTC-QLQ-C30 emotional functioning
subscale (4 items). A sensitivity analysis will be per-
formed to assess the stability of the results to changes in
costs and effectiveness parameters (EORTC QLQ-C15-
PAL quality of life subscale), and differences in health-
care systems between the European countries.
Dissemination
We have set up an Advisory Board of future inter-
national policy users of the project results. The role of
the Advisory Board will be to provide a critical perspec-
tive throughout the life of the project. The project re-
sults will be disseminated through publications in
scientific journals and conferences. To disseminate the
knowledge to all stakeholders we will use the project
website (www.action-acp.eu). A link of ACTION to the
websites of the consortium and Advisory Board mem-
bers will be featured.
Discussion
This project aims to study the effects of the Respecting
Choices program on quality of life and symptoms of pa-
tients with advanced lung or colorectal cancer. This
study has several strengths. First, studies about Advance
Care Planning have mainly been performed with older
nursing home patients. Transferring the concept of ACP
from care of the elderly to patients with advanced can-
cer, who on average are younger and remain competent
for a larger part of their disease trajectory, is a highly
relevant next step in an era of increasing focus on pa-
tient centered healthcare and shared decision-making.
Second, a randomised controlled trial design will enable
us to draw conclusions about the causal relations be-
tween ACP and the outcomes under study. The clus-
tered design of this project prevents contamination
between the control and intervention group. Third, the
unique combination of quantitative and qualitative
methods in this project will result in profound insights
into the underlying working mechanisms of ACP.
In ACTION, we expect to encounter some challenges
and possible limitations. First, patients may decline par-
ticipation for different reasons. They may feel over-
whelmed by the topics raised in the ACP intervention
sessions and may not (yet) feel prepared to talk about
these issues. We will use a patient-centered approach to
facilitate study participation. Patients will receive infor-
mation about the project through their treating special-
ist. Since patients may refuse because they do not want
to engage in ACP conversations, non-response bias can-
not be ruled out. Also selection bias cannot be ruled
out, e.g. in intervention hospitals’ where including physi-
cians may be more likely to ask patients who they think
are more ‘open’ to ACP to participate in the study. If
such ‘gatekeeping’ comes into play, the effect of the
intervention may be overestimated. However, our ap-
proach to systematically assess all lung and colorectal
cancer patients for eligibility, and subsequently invite all
who are eligible to participate in the study may reduce
this risk. Attrition is another potential limitation to this
project. Attrition may occur because the condition of
the patient might worsen such that further participation
becomes impossible, or patients might die during
follow-up. We try to limit attrition by adding the inclu-
sion criterion of a minimal anticipated life-expectancy of
three months and to measure our main outcome meas-
ure at 2.5 months. Third, the international character of
this project might be a challenge, as a balance needs to
be found between on the one hand testing a uniform
intervention in the six countries, that on the other hand
is tailored to the specific cultural, ethical and legal
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context of each country. Fourth, the extent to which ac-
tual care will be reflected in medical files can be ques-
tioned. Potentially, not all treatments that patients
receive will be documented in the hospital medical files.
Conclusion
Advanced cancer typically involves multiple symptoms
and seriously affects patients’ quality of life. Focusing
care at patients’ preferences and open and respectful
communication are important values in end-of-life care,
yet these have been found to be a challenge for health-
care professionals as well as for patients and relatives.
Little is known about the outcomes of formal ACP, the
effects of formal ACP on medical care and medical
decision-making, costs and cost-effectiveness of formal
ACP and country-specific factors that might influence
ACP. Our project will fill these gaps in knowledge, based
on an international multicenter cluster-randomised clin-
ical trial to test the outcomes and effects of a formal
ACP program, which is enriched by a qualitative study
and a cost-effectiveness study.
Contact: www.action-acp.eu
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